Healthcare industry leader joins rapidly growing cost-cycle firm to accelerate the delivery of total solution platform.

GRAND RAPIDS, Mich., May 9, 2023 (Newswire.com) - SpendMend, a leading provider of cost-cycle management solutions for the healthcare industry, announced today that Derick Elliott has joined the company as Chief Commercial Officer. In this role, Derick will oversee the company's sales and marketing efforts while leveraging his experience in healthcare, building platform solutions, and running sales organizations to package, scale, and deliver SpendMend's complete cost-cycle solution.

Derick is a medical technology commercial leader with a track record of building high-performing teams that deliver market-leading results for companies featuring large and diverse solution portfolios. He has previously served in transformational leadership roles for Stryker Corporation and Cardinal Health, including business strategy, M&A integration, and commercialization. He is recognized as a change agent who accelerates growth and helps healthcare entities improve clinical, operational, and financial outcomes.

"I am excited to join SpendMend at such a critical time for the healthcare industry," said Derick. "I am passionate about leveraging technology and data to drive innovation and deliver patient-centric solutions. I am thrilled to join a team that is dedicated to improving financial performance for clients while maintaining an unwavering focus on patient care."

Dan Geelhoed, CEO of SpendMend, added, "We are thrilled to have Derick join our team. He brings a wealth of experience and expertise in healthcare and will be instrumental in driving innovation at SpendMend. We are committed to helping healthcare organizations tackle the challenge of dark data in their supply chain and Derick's experience will be invaluable in that effort."

Steve Rogers, Managing Director at Morgan Stanley Capital Partners, added, "Derick has a demonstrated track record of success in the healthcare industry, and we are excited to see how he will seek to leverage his experience to drive growth and innovation at SpendMend. We are confident that Derick's leadership and strategic vision will help to propel SpendMend to even greater heights."

About SpendMend

SpendMend is the leading provider of tech-enabled, cost-saving solutions in the healthcare industry. By combining data, proprietary technology, and analytics with healthcare expertise, SpendMend partners with healthcare networks to illuminate dark data and expose hidden costs in meaningful ways. The company's mission is to help its clients improve patient care through innovative cost-saving solutions.

Contact Information:
Kylee Savage
Marketing Manager
[email protected]
616-257-8331


Original Source: SpendMend Welcomes Derick Elliott as Chief Commercial Officer

Yang Yang, PhD, of Purdue University is the recipient of a major 5-year grant for Personalized Treatment Development in SCN2A-Related Disorders

EAST LONGMEADOW, Mass., May 9, 2023 (Newswire.com) - The FamilieSCN2A Foundation, a nonprofit organization dedicated to improving the lives of individuals with SCN2A-related disorders (SRDs), has awarded a first-stage $2.5 million dollar research grant to a Purdue University researcher.

Yang Yang, associate professor of Medicinal Chemistry and Molecular Pharmacology in Purdue's College of Pharmacy received the grant to support the development of personalized treatments for this group of disorders after peer-review by scientific experts in the field.

Funding is committed over the next 5 years by a restricted, single-family donation through the FamilieSCN2A Foundation's Hodgkin-Huxley (HH) Research Grant. The grant was named to honor Nobel Prize winners Dr. Alan Hodgkin and Dr. Andrew Huxley for their innovative discovery of action potentials in neurons.

SRDs are a group of rare genetic conditions caused by mutations in the SCN2A gene, which encodes an ion channel that is essential for the function of brain cells. These disorders can cause a wide range of neurological symptoms including difficult-to-control seizures, profound autism, developmental delays, movement disorders, and intellectual disabilities.

The five-year grant will support Yang's research aimed at developing personalized treatments for a splice-site SCN2A variant through n=1 drug development. The goal of n=1 projects is to create treatments tailored to the unique genetic and clinical profiles of individual patients, with the hope of improving outcomes and quality of life for all those affected by these disorders.

"We are incredibly grateful to the family who helped make this grant possible," said Leah Myers, founder of the FamilieSCN2A Foundation. "Through their generosity and commitment to research, this grant will help to accelerate the development of personalized treatments for SRDs, a critical need for families affected by these devastating conditions."

Shawn Egan, Chief Scientific Officer for the FamilieSCN2A Foundation agreed.

"We expect this project to take a large leap forward into the understanding and treatment of SRDs with splice site mutations, which is an area that has been understudied to date," he said.

The FamilieSCN2A Foundation and its scientific advisors reviewed the project proposal prior to awarding the grant and will manage the project to ensure that it meets the highest scientific standards while advancing the foundation's mission.

Yang said he is honored to have received the award and looks forward to the research advances it will enable. 

"I am extremely honored and privileged to receive this grant from the FamilieSCN2A Foundation to embark on this uncharted journey to fight SRD together with the families," he said. "This grant is built on discoveries that were funded by prior FamilieSCN2A Awards and National Institutes of Health (NIH) research grants, which laid a solid foundation for us to take the next giant leap to tackle SRDs.

"With this award, we are excited to build new disease models and work on developing personalized treatments for SRDs, including cutting-edge pharmacological and genetic interventions. We greatly appreciate the trust from the donor family with this substantial award to initiate this high-risk/high-reward research to advance transformative n=1 therapeutic discovery and investigate innovative approaches to drug development for many. I believe this award will help us move closer to a future where individuals with SRDs can receive treatments tailored to their specific needs."

"The award will contribute to the Purdue College of Pharmacy's robust pursuit of impactful discoveries that improve lives," said Eric Barker, Jeannie and Jim Chaney Dean of Pharmacy.

"The Purdue College of Pharmacy is grateful to the FamilieSCN2A Foundation for supporting Dr. Yang's impactful research," he said. "We know that in situations like this, the passion for discovery is fueled by deeply personal motivations for the families involved. We are committed to advancing basic and translational research that helps move discoveries from the laboratory to directly improving patients' lives through new therapeutic interventions."

According to Yang, most rare diseases are genetic disorders and do not have a cure; however, recent progress in precision medicine and gene therapy are offering hope for treating these types of disorders.

The Hodgkin Huxley Award will advance precision and personalized medicine to treat these disorders and improve quality of life for the people affected by them. It will also greatly contribute to ongoing translational research within the Purdue College of Pharmacy's Department of Medicinal Chemistry and Molecular Pharmacology, and the growing drug discovery pipeline at Purdue University, according to Department Head Zhong-Yin Zhang, who also directs Purdue's Institute for Drug Discovery.

"Dr. Yang's research has tremendous potential to improve the lives of countless people through personalized therapies," he said. "We are extremely grateful to the donor family and to the FamilieSCN2A Foundation for their generosity in advancing this incredibly important research."

Yang specializes in neurological diseases, including autism, epilepsy, pain, and dementia; pharmacogenomics; and gene therapy. "He is a leading investigator for the Purdue Institute for Integrative Neuroscience (PIIN)," said Chris Rochet, Professor of Medicinal Chemistry and Molecular Pharmacology and the John and Donna Krenicki Director of PIIN.

PIIN is committed to unraveling mysteries of the healthy brain and advancing treatment of central nervous system disorders.

"Since arriving at Purdue in 2017, Dr. Yang has made important contributions to the field of neuroscience by discovering changes in neuron firing that account for altered brain function in individuals with epilepsy or autism spectrum disorder," Rochet said. "We thank the FamilieSCN2A Foundation for their generous investment in Dr. Yang's research program, and offer our full support to help maximize the long-term impact of this groundbreaking study."

The FamilieSCN2A Foundation is committed to accelerating research, building community, and advocating to improve the lives of those affected by SCN2A-related disorders around the world.

For more information about the FamilieSCN2A Foundation and its mission, or to donate to this cause visit www.scn2a.org.

Contact Information:
Shawn Egan
Chief Scientific Officer
[email protected]

Leah Myers
Founder, Executive Director
[email protected]
3012528070


Original Source: FamilieSCN2A Foundation Announces Inaugural $2.5M Hodgkin-Huxley Research Award

Glorium Technologies, a prominent healthcare software development company, highlights the potential solution to the problem of the global shortage of 18 million healthcare workers in 2030 by enhancing telehealth coverage worldwide.

PRINCETON, N.J., May 9, 2023 (Newswire.com) - According to the World Health Organization (WHO) and the World Bank, there could be a shortage of 18 million health workers by 2030, with developing countries in South Asia and Sub-Saharan Africa expected to be hit the hardest. This factor, coupled with global youth unemployment and limited job prospects, especially in the healthcare industry, presents a challenging situation for access to healthcare worldwide.

Telehealth as an innovative way of connecting patients with physicians could be the answer to ensuring everyone has access to quality healthcare, according to Glorium Technologies experts.

With the COVID-19 outbreak leading to increased demand for remote care, telehealth has grown significantly. However, there is still room for expansion. The market was valued at $83.5 billion in 2022 and is projected to reach $455.26 billion by 2030, with a compound annual growth rate (CAGR) of 24.0% from 2023 to 2030. And here is one of the main reasons why—the Internet and smartphone penetration help to address the gaps in the delivery and availability of telehealth services.

But to make telemedicine accessible for people across the globe, telemedicine coverage should be balanced due to gaping differences in infrastructure and capabilities between countries. Some of them have already established robust networks of remote services for their citizens, and others still need access assistance.

A quick glance at facts and figures shows that in 2022, North America dominated the industry, accounting for 47.1% of the total revenue, mainly due to high healthcare IT expenditure and higher penetration of internet and smartphone users. The Asia Pacific region is projected to witness the fastest growth rate during the forecast period due to the rising geriatric population, combined with advancements in digital health and research initiatives undertaken by key players. Regarding the problems with very low incomes and limited opportunities for employment and education in areas like Africa and South America, patients can receive remote care abroad using telehealth solutions and address health issues in this way. 

"Considering the projected shortage of medical professionals, now is an opportune moment to invest in infrastructure and telehealth software development," says Andrei Kasyanau, CEO and Co-Founder of Glorium Technologies. "In cases where patients cannot receive an accurate diagnosis due to a scarcity of physicians, they can send their test results to medical experts in other regions, who can provide the necessary diagnosis and treatment plans."

In addition to enhancing access to care, telehealth can automate and digitize administrative tasks, freeing up medical professionals' time and enabling them to dedicate more attention to their patients. The technology can also help medical professionals develop networking and exchange valuable information, creating group chats and video rooms for communication and information exchange.

About the company

Glorium Technologies is a top-shelf bespoke software development company that has delivered 100+ products to its clients. The headquarters is located in the US. Since its establishment in 2010, the Company has been helping startups grow by offering top-notch technology designs. Its centers have mastered Business Intelligence, AR/VR, Blockchain, Machine Learning, Big Data, Artificial Intelligence, and many other top tech trends.

Glorium Technologies' achievements are recognized by the international IT community and awarded by the Inc. 5000, Clutch, GoodFirms, AppFutura, Wadline, etc.

Contact Information:
Maksym Arslanov
Content and Communications Specialist
[email protected]


Original Source: Glorium Technologies Discusses How Telehealth Can Help Solve the Expected 18 Million Medical Professional Shortage

The organization was named among the best workplaces in healthcare.

HOBOKEN, N.J., May 9, 2023 (Newswire.com) - Vytalize Health, a leading risk-bearing provider enablement platform, has been selected as one of Inc. magazine's Best Workplaces for 2023. The list, which will be featured in the May/June issue and on Inc.com, is the result of a thorough evaluation of American companies that excel in establishing outstanding workplaces and company culture. 

"Being named to Best Workplaces is an honor that only a small fraction of companies have been able to claim," says Inc. editor-in-chief Scott Omelianuk. "Proving to the world that you're a magnet for talent and have a culture that keeps teams engaged, productive, and proud to come to work is a truly remarkable achievement."

"We are honored to receive this recognition by Inc. magazine. At Vytalize Health, we are dedicated to fostering a culture that values inclusivity, empowerment, and a shared commitment to making a difference. We tackle significant challenges in our work to advance value-based care and always encourage collaboration and support among our employees. We believe that our sense of community and teamwork sets us apart as one of the best places to work," said Faris Ghawi, Co-Founder and CEO.

In 2014, Faris Ghawi and Dr. Amer Alnajar co-founded Vytalize Health to improve healthcare quality and reduce the cost of care through a patient-centered, holistic care delivery model. The company's all-in-one solution, including innovative incentives, smart technology, and a virtual and in-home clinic, empowers independent practices to succeed in value-based care arrangements and has transformed healthcare for hundreds of thousands of patients across the country.

With its ambitious vision of being the best facilitator of people's healing through care that's personalized, evidence-based, and kind, Vytalize Health is making strides by fostering a culture built on a foundation of principles that include transparency, reliability, and optimism. The Vytalize Health team is encouraged to 'think big, but start small' and to 'hold itself to the highest standards' to deliver an unparalleled healthcare experience for its patients. Vytalize Health aims to cultivate a space where its team of high performers feels they are doing their best work and making a sustainable impact on healthcare.

Recently, Vytalize Health closed a $100 million funding round to accelerate its mission of responsible value-based care. Additionally, the company acquired the Independent Physicians of Association of New York, one of the largest physician associations in the US.

About Vytalize Health
Vytalize Health is a risk-bearing provider enablement platform addressing the healthcare industry's biggest challenges with its cutting-edge value-based care delivery system. Vytalize partners with more than 3,000 leading providers to improve the quality of care through evidence-based medicine and a patient experience rooted in kindness. By delivering the right data at the right time in the workflow to physicians and their staff, Vytalize makes its partners more efficient and effective, allowing them to focus on proactive, personalized medicine to improve the value of care and lower costs. Learn more at www.vytalizehealth.com.

Contact Information:
Matt Buder Shapiro
Chief Marketing Officer
[email protected]
+12163370461


Original Source: Vytalize Health Recognized as a Top-Ranking Company on Inc. Magazine's 2023 Best Workplaces List

GLENOLDEN, Pa., May 9, 2023 (Newswire.com) - The letter from the sperm bank landed like a bomb in the midst of the families who had conceived children with Donor X: He had tested positive for one of the genes that cause Charcot-Marie-Tooth disease (CMT), a rare neuromuscular disease that affects one in 2,500 people. 

CMT is a progressive disease of the peripheral nerves that causes people to lose the normal use of their feet, legs, arms and hands. As the nerves die, the muscles around them follow suit. Symptoms include foot deformity (very high arched feet) and foot drop (inability to hold foot horizontal); a slapping gait (feet slap on the floor when walking); loss of muscle in the lower legs, leading to skinny calves; numbness in the feet; and difficulty with balance. In rare cases, hearing, vision and breathing may also be affected.

According to the February 28 letter from the sperm bank, Donor X was asked to submit to genetic testing after one of his offspring tested positive for a likely pathogenic variant in the DMN2 gene. While he had no CMT symptoms and no family history of the disease—he agreed. The sperm bank also recommended that the biological mother be tested. Only the donor's results were positive. 

Based on this result, the letter continued, all offspring of Donor X have a 50 percent chance of inheriting his gene variant and are at risk for symptoms if the variant is determined to cause disease. 

Single mother Erica, 47, got one of those letters. Two of her four children—Frankie, 11 and George, 7—were conceived using Donor X's sperm. Both have a rare form of CMT—Dominant Intermediate B, a group of CMT subtypes in which nerve conduction does not comport with either axonal CMT or demyelinating CMT. Instead, nerve conduction study results are somewhere in between, or intermediate, a term that refers only to nerve conduction and not to disease severity or progression. 

Donor X was an open donor, meaning that his biological children are allowed to contact him when they reach the age of 18. This also meant that there was a portal for parents who had children with the same open donor. When one family contacted Erica through the portal to offer her a vial of Donor X's sperm they no longer needed, she didn't hesitate. The temptation of having the brothers be full siblings was too strong and at the time there was no reason to say no.

Erica knows of 10 kids from seven families who share Donor X's DNA. Many of them have met at Erica's house, spending weeks together and visiting Disney World daily. All of the kids are very much alike, Erica says, sharing personalities, looks and mannerisms. They call each other "diblings," a mashup of donor siblings. 

Frankie first exhibited symptoms at the age of 2. Over the years, his symptoms grew worse, as they do with a progressive disease. Frankie was formally diagnosed with CMT in December 2022, George in February, less than two weeks before the sperm bank letter arrived. 

Today, both brothers are legally deaf and live with apraxia, severe nerve pain and sensory issues. Frankie also has severe breathing issues. While Frankie wears a hearing aid, George communicates solely by signing and the whole family knows American Sign Language. Finding the silver lining in this particular cloud, Erica says that "Frankie teaches us what is coming for George." In the last 18 months, Frankie has lost all muscle tone and started "toe-walking," a typical CMT symptom.

What's extraordinary about the boys is their ability to participate in everyday life. As Erica put it, "Their lives are greatly impacted but not destroyed." They are in a special little league, swim like fishes, golf and play bocce ball. George happily spends hours at a time in the sandbox. But any of those activities can set off paroxysms of pain so bad that Frankie is afraid he's dying. Both take gabapentin with mixed results and Erica is concerned that Frankie's dose keeps getting upped. "You know where that leads," she said.

Erica has two other sons as well: William, 27, an automotive journalist, lives at home with the family, providing crucial support and care. She recently adopted baby Joey, now 8 months, who was born with fetal alcohol syndrome. With the love and care this remarkable family provides, he is improving—and he keeps Frankie happy and distracted. "I am forever grateful for Joey allowing us to show him what love and family truly mean," she said.

While Erica clearly adores all her children, she said she wouldn't have used Donor X's sperm for George if she had been informed about the CMT. "I wouldn't have purposefully had a child who had to go through so much pain." 

Erica is a fighter—and a fierce advocate for her kids. Her advocacy extends to everyone with CMT and her hope is that by being open about her family's story, "[The] specialists and the donors feel compelled to help find treatment for the painful and debilitating symptoms that CMT causes."

In a happy footnote to the story, Frankie was recently accepted to Camp Footprint, the country's only sleepaway camp for kids who have CMT. Fully funded by the Charcot-Marie-Tooth Association (CMTA), Camp Footprint (motto "One Step at a Time") gives kids with CMT a chance to participate in all the regular camp activities like swimming, horseback riding, sports, campfires and music. But they'll also get the experience of connecting to strangers who quickly become friends because they share the same physical and emotional challenges. Campers get the chance to feel understood, to be normal, and to blend in instead of standing out.

The CMTA is the leading patient advocacy organization driving CMT research. Its mission is to develop treatments and a cure for the 3 million people worldwide who live with the disease, while improving the quality of life for patients and their families. The CMTA has invested $23.5 million in the search for a cure and its Strategy to Accelerate Research (STAR) brings world-renowned CMT researchers together with pharmaceutical and biotechnology partners and patients to accelerate scientific breakthroughs. The CMTA also offers community services, including 70 local branches, educational materials and patient conferences. To learn more about the CMTA, please visit www.cmtausa.org.

Contact Information:
Sarah Kaider
Digital Marketing Manager, Charcot-Marie-Tooth Association
[email protected]

Marcia Semmes
Media Contact, Charcot-Marie-Tooth Association
[email protected]


Original Source: Charcot-Marie-Tooth Association: Sperm Donor With CMT Gene Passes It on to Multiple Families

BANGKOK, May 9, 2023 (Newswire.com) - HOYA Vision Care, a leader in optical technology innovation, continues to roll out the MiYOSMART sun range, with a planned reach of 30 countries, over the next few months following the soft launch in April 2023. The photochromic spectacle lenses, MiYOSMART Chameleon, and polarised spectacle lenses, MiYOSMART Sunbird, were developed to slow down myopia progression in children using D.I.M.S. Technology while providing protection from intense sunlight.[1-5] These two new products, along with the MiYOSMART clear spectacle lenses which launched in 2018, give children the freedom to comfortably take part in the activities they enjoy indoors and outdoors without compromising their eyesight. 

MiYOSMART Chameleon and MiYOSMART Sunbird both provide protection from intense sunlight while simultaneously correcting the myopic refractive error and slowing myopia progression.[1-5] The new spectacle lenses utilise the same D.I.M.S. Technology used in the award-winning [6,7] and noninvasive MiYOSMART clear spectacle lenses, shown to slow myopia progression by 60% in children aged 8 to 13.[3] Due to its HOYA photochromic lens technology, MiYOSMART Chameleon is an all-in-one solution to myopia management and protected outdoor activity. It rapidly adapts to the level of sunlight and fades back to clear indoors in seconds.[8] Meanwhile, MiYOSMART Sunbird is the ideal addition to MiYOSMART clear spectacle lenses for extra protection from intense sunlight and glare.[1,9,10] It also offers vibrant colours and rich contrast in bright light, allowing children to fully experience the beauty of outdoors.[11] 

"Children's vision is worth protecting. By acting today, we give them more opportunity tomorrow," said Frederiek Ysebaert, Managing Director of the Pediatric Care Business Unit at HOYA Vision Care. "With the launch of MiYOSMART sun spectacle lenses, inspired by our discussions with eye care professionals, we can enable children across the world to spend more time outdoors while protecting their eyes from intense sunlight, maximising the benefits of D.I.M.S. Technology on myopia progression." 

Alongside the launch of the MiYOSMART sun range, HOYA Vision Care will launch "protect how they see the world," a dedicated global campaign to raise awareness of the importance of outdoor time and sun protection in children. Spending time outdoors may slow down myopia progression in children[6,7], and as such it is the most common recommended behavioural management for myopia given by eye care professionals.[8] However, as the majority of lifetime sun exposure occurs under the age of 21, it is necessary to prevent long-term eye damage to children's eyes with effective and reliable sun protection.[1,9] This is particularly important for myopic children using atropine eyedrops for myopia management, and those that are light-sensitive.[2,10,11] 

From the launch in 2018 until the end of 2022, over four million MiYOSMART spectacle lenses were purchased by parents across the world.[18] With the launch of MiYOSMART Chameleon and MiYOSMART Sunbird, HOYA Vision Care will continue to help fight and control the growing problem of myopia around the world. 

Product Disclaimer: MiYOSMART spectacle lenses have not been approved for use in the management of myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S. 

About HOYA Vision Care

For over 60 years, HOYA Vision Care has been a passionate and global leader in optical technology innovation. As a manufacturer of high-quality, high-performing eyeglass lenses, HOYA continuously aims to bring the best possible vision care solutions to eye care professionals and their patients around the world. The company supplies lenses in 110 countries with a network of over 17,000 employees and 43 laboratories around the globe.

References 

1. WSPOS. Sunlight Exposure & Children's Eyes Consensus Statement. 2016. Available at: https://www.wspos.org/wspos-sunlight-exposure-childrens-eyes-consensus-statement/ (Last accessed 28/03/2023) 

2. Wu PC, Chuang MN, Choi J, et al. Update in myopia and treatment strategy of atropine use in myopia control. Eye (Lond). 2019;33(1):3-13. 

3. Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-368. 

4. Lakkis C, Weidemann K. Evaluation of the performance of photochromic spectacle lenses in children and adolescents aged 10 to 15 years. Clin Exp Optom. 2006;89(4):246-252. . 

5. Renzi-Hammond LM, Hammond BR Jr. The effects of photochromic lenses on visual performance. Clin Exp Optom. 2016;99(6):568-574. 

6. Winners of the exhibition's grand prix. Inventions Geneva. N.D. Available from: https://inventions-geneva.ch/en/winners/ (Last accessed 28/03/2023) 

7. Winners 2020. Silmo Paris. 2020. https://en.silmoparis.com/SILMO-d-OR/SILMO-dOrAwards/2020-Winners# (Last accessed 28/03/2023). 

8. Hoya data on file. HOYA Internal Product Performance Validation. 09/2022 

9. Hoya data on file. UVA and UVB transmittance for MiYOSMART photochromic and polarized sun spectacle lenses. 07/2022 

10. Hoya data on file. Luminous transmittance for MiYOSMART polarized sun spectacle lenses. 07/2022 

11. Quintana MS, Langa A, del Moral-Martinez I, et al. Polarized Filters Enhance Contrast Sensitivity When Glare Is Produced On A Flat Surface Under Photopic Conditions. Invest Ophthalmol Vis Sci. 2006;47(13):1225.

12. Ho CL, Wu WF, Liou YM. Dose-Response Relationship of Outdoor Exposure and Myopia Indicators: A Systematic Review and Meta-Analysis of Various Research Methods. Int J Environ Res Public Health. 2019;16(14):2595. 

13. Jonas JB, Ang M, Cho P, et al. IMI prevention of myopia and its progression. Invest Ophthalmol Vis Sci. 2021;62(5):6. 

14. WSPOS. Myopia Survey Data. November 2022. Presented as part of WSPOS Symposium: Comprehensive Update on Myopia Management.19-20 November 2022. Available from: http://forum.wspos.org/symposium-part-1-comprehensive-update-on-myopia-management-2 

15. Prevent Blindness. Children's Eyes are More Susceptible to Long-Term Damage from UV Rays. 2011. Available at: https://preventblindness.org/childrens-eyes-are-more-susceptible-to-longtermdamage-from-uv-rays/ (Last accessed 28/03/2023) 

16. Li FF, Yam JC. Low-Concentration Atropine Eye Drops for Myopia Progression. Asia Pac J Ophthalmol (Phila). 2019;8(5):360-365. 

17. Gong Q, Janowski M, Luo M, et al. Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis. JAMA Ophthalmol. 2017;135(6):624-630. 

18. Based on number of MiYOSMART lenses sold as per Hoya sales data on file as of December 2022.

Contact Information:
Susan Brown
PR Lead
[email protected]
8312334616
Related Images


Original Source: HOYA Vision Care Launches MiYOSMART Sun Spectacle Lenses Combining Protection From Intense Sunlight With Myopia Management